Micafungin
Yes
No
No
Active ingredient: Micafungin
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
08/02/2023 Echinocandins for treating invasive candidiasis
The Ministry of Health’s Drug Advisory Committee has recommended:
Anidulafungin 100 mg injection
in line with its registered indications for treating invasive candidiasis in view of favourable clinical and cost-effectiveness compared with other echinocandins.
Funding status
[R] Anidulafungin 100 mg injection is recommended for inclusion on the MOH Standard Drug List (SDL) from 1 April 2023.
[NR] Subsidy does not apply to micafungin 50 mg injection or caspofungin 50 mg and 70 mg injections.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Injection, Powder, Lyophilized, For Solution 50 mg/vial |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intravenous
MICAFUNGIN BIOCON POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIAL [SIN17407P]*
MICAFUNGIN BIOCON POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/VIAL [SIN17406P]*
MICAFUNGIN PHARMAZAC POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL [SIN17264P]*
MICAFUNGIN-AFT POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL [SIN17429P]*
MYCAMINE POWDER FOR SOLUTION FOR INFUSION 50MG/VIAL [SIN14464P]*
* Clinical information is available for this product.
